SKYE's cash position collapsed 91% to $5.9M while net losses more than doubled, creating a severe liquidity crisis for this clinical-stage biotech company.
The dramatic cash burn acceleration combined with the near-depletion of cash reserves creates an immediate going concern risk, as the company likely has insufficient funding to complete ongoing clinical trials. The acquisition of Bird Rock Bio appears to have consumed significant resources while R&D expenses doubled, suggesting increased operational complexity without corresponding revenue generation.
SKYE's financial position deteriorated dramatically with cash plummeting from $68.4M to $5.9M while net losses doubled to $55.9M and operating cash flow worsened 71% to negative $43.1M. Current liabilities nearly doubled to $8.2M while stockholders' equity collapsed 71% to $20M, reflecting both the cash burn and likely dilutive equity raises. The financial profile signals a company in severe distress that will need immediate capital infusion to continue operations and fund its clinical programs.
Receivables surged 266.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income declined 110.5% — review whether driven by operations, interest costs, or non-recurring items.
R&D investment increased 105.1% — signals commitment to future product development, though near-term margin impact.
Capex reduced 99.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash declined 91.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current liabilities surged 89.1% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 79.7% — significant increase in debt or obligations, assess impact on financial flexibility.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Operating cash flow fell 70.6% — earnings quality concerns; investigate working capital changes and non-cash items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →